DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Asmanex (Mometasone Furoate Inhalation) - Published Studies

 
 



Asmanex Related Published Studies

Well-designed clinical trials related to Asmanex (Mometasone Inhalation)

The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. [2011.06]

Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. [2010.12]

Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. [2010.07]

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. [2010.01.05]

Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. [2010.01]

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. [2010.01]

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. [2010]

Once-Daily Evening Dosing of Mometasone Furoate Administered Via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis. [2009.09.14]

Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]

Effects of mometasone furoate administered via a dry powder inhaler once daily in the evening on nocturnal lung function and sleep parameters in patients with moderate persistent asthma : a randomized, double-blind, placebo-controlled pilot study. [2009]

Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler. [2008.10]

Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. [2008.04]

Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. [2007.03]

Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. [2006.11]

Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. [2005.12]

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. [2005.08]

Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. [2005.07]

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. [2005.03]

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. [2004.11.01]

Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. [2003.06]

Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. [2001.08.15]

Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. [2001.04]

Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. [2001.02]

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. [2000.12]

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. [2000.11]

Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. [2000.11]

Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. [2000.10]

Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. [2000.05]

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. [1997.09]

Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. [1996.08]

Well-designed clinical trials possibly related to Asmanex (Mometasone Inhalation)

Olfactory cleft inflammation is present in seasonal allergic rhinitis and is reduced with intranasal steroids. [2010.07]

Olfactory cleft inflammation is present in seasonal allergic rhinitis and is reduced with intranasal steroids. [2010]

Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function. [2008.10]

Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis. [2008.07]

Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. [2006.10]

Ethical assessment of industry-sponsored clinical trials: a case analysis. [2002.04]

Increased levels of airway neutrophils reduce the inhibitory effects of inhaled glucocorticosteroids on allergen-induced airway eosinophils. [2002.01]

Other research related to Asmanex (Mometasone Inhalation)

Vandetanib: in medullary thyroid cancer. [2012]

Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. [2011.07]

Treatment with inhaled mometasone furoate reduces short-acting beta(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. [2011.03]

An assessment of change in asthma control among adolescents and adults with persistent asthma in mometasone furoate/formoterol fumarate clinical trials. [2011.02]

Comparison of high-dose salmeterol/fluticasone and moderate-dose salmeterol/fluticasone plus low-dose mometasone in patients with severe persistent asthma. [2011]

Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. [2010.11]

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. [2010.06]

Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. [2010]

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. [2010]

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. [2010]

Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges. [2009.12]

Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. [2009.08]

Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. [2009.07.13]

Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. [2009.05]

Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma. [2008.11]

Mometasone furoate dry-powder inhaler for the control of persistent asthma. [2007.11]

Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma. [2007.11]

Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. [2007.11]

Eletriptan: a review of its use in the acute treatment of migraine. [2006]

Concentration-dependent activity of mometasone furoate and dexamethasone on blood eosinophils isolated from atopic children: modulation of Mac-1 expression and chemotaxis. [2004.12.15]

[The effect of mometasone furoate on mucociliary clearance in patients with perennial allergic rhinitis] [2003.10]

A prospective study on the efficacy of mometasone furoate monohydrate aqueous nasal spray on Chinese patients with allergic rhinitis. [2003.04]

[Effectiveness of mometasone furoate nasal spray in seasonal allergic rhinitis. First experiences in practice after the introduction of the drug in Hungary] [2002.08.18]

A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. [2001.09]

Drug delivery performance of the mometasone furoate dry powder inhaler. [2001.01]

Telmisartan: a review of its use in hypertension. [2001]

Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. [2000.12]

Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. [1998.04]

Other possibly related research studies

Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. [2007.07]

Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. [2007]

Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma. [2007.01]

Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. [2007.02]

Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. [2006.03]

[The role of leukotriene D4 antagonist in allergic rhinitis with steroid resistance] [2005.06]

Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. [2005.08]

Effects of inhaled corticosteroids on bone. [2005.01]

Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. [2004.11]

Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. [2004]

Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. [2003.10]

Safety of the newer inhaled corticosteroids in childhood asthma. [2003]

Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. [2002]

A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. [2002.01]

The linear relationship between changes in childhood growth velocity and topical glucocorticoid dose. [2001.05]

An easy-to-use dry-powder inhaler. [2000.11]

Development of fluticasone propionate and comparison with other inhaled corticosteroids. [1998.04]

The treatment of asthma in children: inhaled corticosteroids. [2007]

Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. [2009.07]

Transrepression and transactivation potencies of inhaled glucocorticoids. [2008.12]

Inhaled corticosteroids for asthma: are they all the same? [2009.02]

Allergic contact dermatitis to inhalation corticosteroids. [2010.01]

Assessment of pharmacists' opinions toward the behind-the-counter category of medications. [2011.07]

Updates on the use of inhaled corticosteroids in asthma. [2011.08]

Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. [2010.09.25]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014